Login to Your Account



NewCo News: P2D Bioscience Aims Weapons At CNS, Pulmonary Disorders

By Marie Powers


Tuesday, August 2, 2011
With $9 million raised to date and nine compounds in clinical and preclinical development, P2D Bioscience Inc. already has traction in its efforts to advance product candidates for central nervous system and pulmonary disorders, including attention deficit/hyperactivity disorder (ADHD), obesity, anxiety, depression, Alzheimer's disease, traumatic brain injury and chronic obstructive pulmonary disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription